Free Trial

Nyxoah Q3 2023 Earnings Report

Nyxoah logo
$10.50 +0.12 (+1.16%)
As of 01/30/2025 03:59 PM Eastern

Nyxoah EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
$1.50 million
Beat/Miss
Missed by -$440.00 thousand
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Nyxoah Earnings Headlines

Publication relating to transparency notifications
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Nyxoah SA Ordinary Shares
Nyxoah: The Future Of OSA
Publication relating to transparency notifications
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat